Skip to content

docs: add PK model references to Credits #304

New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Merged
fantuanmtf merged 1 commit into from
Nov 11, 2026
Merged

docs: add PK model references to Credits #304

Show file tree
Hide file tree
Changes from all commits
Commits
Show all changes
1 commit
Select commit
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
2 changes: 1 addition & 1 deletion Algorithm Explanation.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -533,7 +533,7 @@ $$

## 20) 内源性睾酮压制（transfem，辅助抗雄激素，默认锚定基线）

- **状态**：雌二醇通过下丘脑/垂体负反馈压制 LH/FSH，从而降低内源性睾酮。生理剂量下仅为**部分**压制（transfemscience.org intro；Leinung 2018：E2 < 50 pg/mL 时 TT ~160 ng/dL，E2 100–150 pg/mL 时 ~50 ng/dL）；完全压制到女性范围通常需要超生理剂量雌二醇或抗雄激素/GnRH 激动剂（Misakian 2025 PMID 40639470：睾丸未切除者注射雌二醇单药 82.6% 达 TT < 50 ng/dL）。睾丸切除后睾酮降至 ~10–30 ng/dL 并在继续雌二醇下稳定（van der Sluis 2022 PMID 36201493）。因此本模型把雌二醇的压制作为**抗雄激素的辅助前提**，而非替代。
- **状态**：雌二醇通过下丘脑/垂体负反馈压制 LH/FSH，从而降低内源性睾酮。生理剂量下仅为**部分**压制（transfemscience.org intro；Leinung 2018：E2 < 50 pg/mL 时 TT ~160 ng/dL，E2 100–150 pg/mL 时 ~50 ng/dL）；完全压制到女性范围通常需要超生理剂量雌二醇或抗雄激素/GnRH 激动剂（Misakian 2025 PMID 40639470：睾丸未切除者注射雌二醇单药 82.6% 达 TT < 50 ng/dL）。睾丸切除后睾酮降至 ~10–30 ng/dL 并在继续雌二醇下稳定（Collet 2023 PMID 36201493）。因此本模型把雌二醇的压制作为**抗雄激素的辅助前提**，而非替代。

- **模型**：给定基线睾酮 $T_0$（ng/dL，来自用户首次血检），在雌二醇浓度 $E$（pg/mL）下的剩余分数
$$
Expand Down
2 changes: 1 addition & 1 deletion docs/todo/day/024-phase-a6-assay.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -20,4 +20,4 @@ $$

## References

- [Rosner 2013 — Estradiol Assay Comparison](https://pubmed.ncbi.nlm.nih.gov/23457408/)
- [Rosner 2013 — Estradiol Assay Comparison](https://pubmed.ncbi.nlm.nih.gov/23463657/)
2 changes: 1 addition & 1 deletion docs/todo/day/025-phase-a7-covariate.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -20,5 +20,5 @@ $$

## References

- [Stanczyk 2022 — popPK template](https://pubmed.ncbi.nlm.nih.gov/36574387/)
- [Stanczyk 2022 — population PK model for transdermal steroid delivery](https://pubmed.ncbi.nlm.nih.gov/36574387/)
- [Alotaibi 2026 — Metoprolol PK in Trans Women](https://pubmed.ncbi.nlm.nih.gov/42878231/)
2 changes: 1 addition & 1 deletion docs/todo/day/027-phase-a9-pkdebug.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -19,4 +19,4 @@ $$

## References

- [Stanczyk 2022 — popPK template](https://pubmed.ncbi.nlm.nih.gov/36574387/)
- [Stanczyk 2022 — population PK model for transdermal steroid delivery](https://pubmed.ncbi.nlm.nih.gov/36574387/)
2 changes: 1 addition & 1 deletion docs/todo/day/028-phase-b-plan-transmasc.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -16,6 +16,6 @@ and T-driven endogenous E2.
## References

- [Defreyne 2019 — Transmasculine Hormone Therapy](https://pubmed.ncbi.nlm.nih.gov/31027545/)
- [Madsen 2021 — Erythrocytosis in Trans Men](https://pubmed.ncbi.nlm.nih.gov/33904934/)
- [Madsen 2021 — Erythrocytosis in Trans Men](https://pubmed.ncbi.nlm.nih.gov/33599731/)
- [Turner 2019 — SC Testosterone Undecanoate PK](https://pubmed.ncbi.nlm.nih.gov/31384715/)
- [Figueiredo 2022 — SC Testosterone Injections](https://pubmed.ncbi.nlm.nih.gov/34698352/)
340 changes: 340 additions & 0 deletions src/data/pkReferences.ts
View file
Open in desktop
Original file line number Diff line number Diff line change
@@ -0,0 +1,340 @@
/**
* Papers and guidance used by the pharmacokinetic model work tracked from
* issue #200 onward. Kept as static data so the Credits page still loads
* nothing from third parties.
*
* Each row is a link plus one line saying what the model uses it for. The
* list is deliberately grouped; a flat list of fifty citations is hard to
* scan. Add new sources to the group they inform.
*/
export interface PkReference {
/** Short citation, written to be scanned rather than copied. */
name: string;
/** PubMed, DOI, or the guidance page itself. */
href: string;
/** Journal and what the model uses the source for. */
desc: string;
}

export interface PkReferenceGroup {
title: string;
references: PkReference[];
}

export const PK_REFERENCE_GROUPS: PkReferenceGroup[] = [
{
title: 'Estradiol, SHBG, and free hormone',
references: [
{
name: 'Narinx et al., 2022 — SHBG and the free-hormone hypothesis',
href: 'https://pubmed.ncbi.nlm.nih.gov/36205798/',
desc: 'Cell Mol Life Sci. SHBG binding and free-testosterone interpretation.',
},
{
name: 'Södergård et al., 1982 — Free and bound testosterone and estradiol',
href: 'https://doi.org/10.1016/0022-4731(82)90038-3',
desc: 'J Steroid Biochem. Binding model used for free-hormone fractions.',
},
{
name: 'Dunn et al., 1981 — Steroid binding to SHBG and CBG',
href: 'https://pubmed.ncbi.nlm.nih.gov/7195404/',
desc: 'J Clin Endocrinol Metab. Binding affinities for free-hormone calculation.',
},
{
name: 'Ropponen et al., 2005 — Oral vs transdermal estradiol and SHBG',
href: 'https://pubmed.ncbi.nlm.nih.gov/15784702/',
desc: 'J Clin Endocrinol Metab. Route-dependent SHBG changes.',
},
{
name: 'Rosner et al., 2013 — Estradiol measurement position statement',
href: 'https://pubmed.ncbi.nlm.nih.gov/23463657/',
desc: 'J Clin Endocrinol Metab. Assay limitations behind the estradiol inputs.',
},
{
name: 'Stanczyk et al., 2022 — Population PK of a transdermal steroid',
href: 'https://pubmed.ncbi.nlm.nih.gov/36574387/',
desc: 'PLoS One. Population-PK structure and predicted hormone levels.',
},
{
name: 'Zhang et al., 2024 — Oral estradiol valerate PK',
href: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11246651/',
desc: 'PMC. Oral EV half-life, Tmax, and exposure used for kE1Pool.',
},
{
name: 'Fiers et al., 2018 — Free testosterone by LC-MS/MS dialysis',
href: 'https://pubmed.ncbi.nlm.nih.gov/29618085/',
desc: 'J Clin Endocrinol Metab. Free-T calculation and assay comparison.',
},
],
},
{
title: 'Transmasculine testosterone: dosage forms',
references: [
{
name: 'Swerdloff et al., 2020 — Oral testosterone undecanoate',
href: 'https://pubmed.ncbi.nlm.nih.gov/32382745/',
desc: 'J Clin Endocrinol Metab. PK of a self-emulsifying oral TU formulation.',
},
{
name: 'Yin et al., 2012 — Oral testosterone undecanoate PK',
href: 'https://pubmed.ncbi.nlm.nih.gov/21474786/',
desc: 'J Androl. Re-examined oral TU pharmacokinetics.',
},
{
name: 'Rogol et al., 2016 — Testosterone nasal gel',
href: 'https://pubmed.ncbi.nlm.nih.gov/26695758/',
desc: 'Andrology. PK of a nasal testosterone gel.',
},
{
name: 'Handelsman et al., 1990 — Testosterone pellets',
href: 'https://pubmed.ncbi.nlm.nih.gov/2115044/',
desc: 'J Clin Endocrinol Metab. Pellet PK and androgen response.',
},
{
name: 'McCullough et al., 2014 — Testosterone pellet review',
href: 'https://pubmed.ncbi.nlm.nih.gov/25999802/',
desc: 'Curr Sex Health Rep. Pellet dosing and duration context.',
},
{
name: 'Figueiredo et al., 2022 — Subcutaneous testosterone injections',
href: 'https://pubmed.ncbi.nlm.nih.gov/34698352/',
desc: 'J Clin Endocrinol Metab. SC injection PK and practicality.',
},
{
name: 'Turner et al., 2019 — Subcutaneous testosterone undecanoate',
href: 'https://pubmed.ncbi.nlm.nih.gov/31384715/',
desc: 'J Endocr Soc. SC TU PK and acceptability.',
},
{
name: 'Mazer et al., 2005 — Testosterone patch vs gel',
href: 'https://pubmed.ncbi.nlm.nih.gov/16422889/',
desc: 'J Sex Med. Steady-state PK and variability by route.',
},
{
name: 'Swerdloff et al., 2000 — Long-term transdermal testosterone gel',
href: 'https://pubmed.ncbi.nlm.nih.gov/11134099/',
desc: 'J Clin Endocrinol Metab. Long-term testosterone gel PK.',
},
{
name: 'Marbury et al., 2003 — Testim vs AndroGel',
href: 'https://pubmed.ncbi.nlm.nih.gov/12673669/',
desc: 'Biopharm Drug Dispos. Comparative topical testosterone gel PK.',
},
],
},
{
title: 'Transmasculine testosterone: safety and context',
references: [
{
name: 'da Silva et al., 2024 — Uterine changes on testosterone',
href: 'https://pubmed.ncbi.nlm.nih.gov/39049785/',
desc: 'Eur J Endocrinol. Uterine effects of testosterone therapy.',
},
{
name: 'Canbolat et al., 2026 — Uterine and ovarian histopathology',
href: 'https://pubmed.ncbi.nlm.nih.gov/42796076/',
desc: 'J Clin Med. Histopathological effects of testosterone therapy.',
},
{
name: 'Barrera et al., 2023 — Testosterone concerns after hysterectomy',
href: 'https://pubmed.ncbi.nlm.nih.gov/35850361/',
desc: 'J Pediatr Adolesc Gynecol. T management after hysterectomy and oophorectomy.',
},
{
name: 'Reilly et al., 2019 — Knowledge gaps in gender-affirming surgery',
href: 'https://pubmed.ncbi.nlm.nih.gov/31503150/',
desc: 'Obstet Gynecol. Evidence gaps around hysterectomy and oophorectomy.',
},
{
name: 'Light et al., 2014 — Pregnancy after transition',
href: 'https://pubmed.ncbi.nlm.nih.gov/25415163/',
desc: 'Obstet Gynecol. Pregnancy and fertility after testosterone exposure.',
},
{
name: 'Barrero et al., 2023 — Fertility preservation on testosterone',
href: 'https://pubmed.ncbi.nlm.nih.gov/37810944/',
desc: 'Transgend Health. Oocyte retrieval during and after testosterone.',
},
{
name: 'Nackeeran et al., 2022 — Testosterone route and hematocrit',
href: 'https://pubmed.ncbi.nlm.nih.gov/34445892/',
desc: 'J Urol. Route-specific hematocrit changes.',
},
{
name: 'Madsen et al., 2021 — Erythrocytosis in trans men',
href: 'https://pubmed.ncbi.nlm.nih.gov/33599731/',
desc: 'J Clin Endocrinol Metab. Long-term hematocrit risk.',
},
{
name: 'Okano et al., 2025 — Testosterone formulations and hematocrit',
href: 'https://pubmed.ncbi.nlm.nih.gov/39011565/',
desc: 'Andrology. Systematic review of formulation effects on hematocrit.',
},
{
name: 'Okano et al., 2025 — 100 mg testosterone cypionate and erythrocytosis',
href: 'https://pubmed.ncbi.nlm.nih.gov/41052128/',
desc: 'J Sex Med. Randomized pilot on dose and erythrocytosis.',
},
{
name: 'Nimitpanya et al., 2026 — Body fat and composition on testosterone',
href: 'https://pubmed.ncbi.nlm.nih.gov/42170522/',
desc: 'Transgend Health. Short-term body-composition changes.',
},
{
name: 'Lundberg et al., 2024 — Fat, muscle, and cardiometabolic changes',
href: 'https://pubmed.ncbi.nlm.nih.gov/39604308/',
desc: 'J Intern Med. Five-year body-composition context.',
},
{
name: 'Dela Cruz et al., 2023 — Mouse model of pubertal suppression and T',
href: 'https://pubmed.ncbi.nlm.nih.gov/36484619/',
desc: 'Hum Reprod. Preclinical model for transmasculine treatment.',
},
{
name: "T'Sjoen et al., 2019 — Endocrinology of transgender medicine",
href: 'https://pubmed.ncbi.nlm.nih.gov/30307546/',
desc: 'Endocr Rev. Clinical endocrinology and treatment context.',
},
{
name: 'Costa et al., 2018 — Testosterone recommendations for trans men',
href: 'https://pubmed.ncbi.nlm.nih.gov/29913543/',
desc: 'Rev Bras Ginecol Obstet. Brazilian clinical recommendations.',
},
{
name: 'Spanos et al., 2020 — Insulin resistance and body composition',
href: 'https://pubmed.ncbi.nlm.nih.gov/32180895/',
desc: 'World J Diabetes. Metabolic effects of gender-affirming hormone therapy.',
},
{
name: 'Ford et al., 2022 — Body composition and bone health',
href: 'https://pubmed.ncbi.nlm.nih.gov/35509260/',
desc: 'J Hum Nutr Diet. Body-composition and bone outcomes.',
},
{
name: 'Carbonnel et al., 2021 — The uterus in transgender men',
href: 'https://pubmed.ncbi.nlm.nih.gov/34364678/',
desc: 'Fertil Steril. Uterine effects and gynecologic care.',
},
{
name: 'Cheung et al., 2024 — Physical performance on GAHT',
href: 'https://pubmed.ncbi.nlm.nih.gov/37437247/',
desc: 'J Clin Endocrinol Metab. Performance and body-composition context.',
},
{
name: 'Iannantuoni et al., 2021 — Inflammation and leukocyte-endothelium',
href: 'https://pubmed.ncbi.nlm.nih.gov/33032814/',
desc: 'Fertil Steril. Vascular and inflammatory effects of testosterone.',
},
],
},
{
title: 'HPG axis, anti-androgens, and suppression',
references: [
{
name: 'Misakian et al., 2025 — Injectable estradiol monotherapy',
href: 'https://pubmed.ncbi.nlm.nih.gov/40639470/',
desc: 'Endocr Pract. Estradiol monotherapy suppression of endogenous testosterone.',
},
{
name: 'Cortez et al., 2023 — TREAT study protocol',
href: 'https://pubmed.ncbi.nlm.nih.gov/38133914/',
desc: 'JMIR Res Protoc. Estradiol regimen comparison and safety.',
},
{
name: 'Collet et al., 2023 — Testosterone and adrenal androgens after gonadectomy',
href: 'https://pubmed.ncbi.nlm.nih.gov/36201493/',
desc: 'J Clin Endocrinol Metab. Androgen changes with and without gonadectomy.',
},
{
name: 'Hümpel et al., 1977 — Cyproterone acetate bioavailability',
href: 'https://pubmed.ncbi.nlm.nih.gov/880829/',
desc: 'Contraception. Oral cyproterone acetate pharmacokinetics.',
},
{
name: 'Lee et al., 2009 — Bicalutamide pharmacokinetics',
href: 'https://pubmed.ncbi.nlm.nih.gov/20110037/',
desc: 'Clin Ther. Bicalutamide formulation pharmacokinetics.',
},
{
name: 'Overdiek et al., 1985 — Spironolactone pharmacokinetics',
href: 'https://pubmed.ncbi.nlm.nih.gov/4042530/',
desc: 'Clin Pharmacol Ther. Spironolactone pharmacokinetics.',
},
{
name: 'Zhou et al., 1998 — Medroxyprogesterone acetate pharmacokinetics',
href: 'https://pubmed.ncbi.nlm.nih.gov/9693401/',
desc: 'Contraception. MPA pharmacokinetics after injection.',
},
{
name: 'Sennello et al., 1986 — Leuprolide pharmacokinetics',
href: 'https://pubmed.ncbi.nlm.nih.gov/3083092/',
desc: 'J Pharm Sci. IV and subcutaneous leuprolide pharmacokinetics.',
},
{
name: 'Bouchot et al., 1998 — Triptorelin pharmacokinetics and pharmacodynamics',
href: 'https://pubmed.ncbi.nlm.nih.gov/9701702/',
desc: 'Horm Res. Three-month triptorelin pharmacokinetics and pharmacodynamics.',
},
],
},
{
title: 'Monitoring, assays, and population PK',
references: [
{
name: "O'Connell et al., 2022 — Cardiometabolic outcomes in trans youth",
href: 'https://pubmed.ncbi.nlm.nih.gov/36221797/',
desc: 'J Clin Endocrinol Metab. Cardiometabolic monitoring context.',
},
{
name: 'Hamidi et al., 2019 — Transfeminine hormone therapy',
href: 'https://pubmed.ncbi.nlm.nih.gov/31027544/',
desc: 'Endocrinol Metab Clin North Am. Clinical transfeminine care.',
},
{
name: 'Defreyne et al., 2019 — Transmasculine hormone therapy',
href: 'https://pubmed.ncbi.nlm.nih.gov/31027545/',
desc: 'Endocrinol Metab Clin North Am. Clinical transmasculine care.',
},
{
name: 'Alotaibi et al., 2026 — Metoprolol PK on gender-affirming therapy',
href: 'https://pubmed.ncbi.nlm.nih.gov/42878231/',
desc: 'Xenobiotica. Drug-PK interaction context for GAHT.',
},
{
name: 'Pouw et al., 2024 — Laboratory monitoring of GAHT',
href: 'https://pubmed.ncbi.nlm.nih.gov/38452266/',
desc: 'J Appl Lab Med. Monitoring and assay practice.',
},
],
},
{
title: 'Labels and guidelines',
references: [
{
name: 'WPATH Standards of Care, version 8',
href: 'https://doi.org/10.1080/26895269.2022.2100644',
desc: 'Treatment and monitoring framework for gender-affirming care.',
},
{
name: 'Endocrine Society guideline, 2017',
href: 'https://doi.org/10.1210/jc.2017-01658',
desc: 'Endocrine treatment of gender-dysphoric and gender-incongruent persons.',
},
{
name: 'UCSF Gender Affirming Health Program',
href: 'https://transcare.ucsf.edu/guidelines',
desc: 'Masculinizing and feminizing hormone therapy guidance.',
},
{
name: 'Drug labels and prescribing information',
href: 'https://github.com/xunxunProjects/Oyama-s-HRT-Tracker/blob/main/Algorithm%20Explanation.md',
desc: 'EstroGel, Divigel, Climara, Vivelle-Dot, AndroGel, Angeliq, Xyosted, Aveed, Azmiro, Nebido, and Androcur/Dianette.',
},
],
},
];

export const PK_REFERENCE_COUNT = PK_REFERENCE_GROUPS.reduce(
(total, group) => total + group.references.length,
0,
);
Loading
Loading